Patents by Inventor Mark Andrew Murcko

Mark Andrew Murcko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11340231
    Abstract: Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: May 24, 2022
    Assignee: DEWPOINT THERAPEUTICS, INC.
    Inventors: Alexander Szewczak, Ina Poser, Mark Andrew Murcko, Stephen Paul Hale, Bruce Aaron Beutel
  • Publication number: 20210208153
    Abstract: Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Inventors: Alexander SZEWCZAK, Ina POSER, Mark Andrew MURCKO, Stephen Paul HALE, Bruce Aaron BEUTEL
  • Patent number: 10934302
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 2, 2021
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien
  • Publication number: 20200392161
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 17, 2020
    Inventors: W. Patrick Walters, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Alexander M. Taylor, Levi Charles Thomas Pierce, Mark Andrew Murcko, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Kyle Konze, Markus Kristofer Dahlgren, Eric Therrien
  • Publication number: 20200284801
    Abstract: Methods of assessing, such as characterizing or determining, condensate-associated characteristics of a compound, such as a test compound, and applications thereof are provided. For example, methods of determining a partition characteristic of a test compound in a target condensate, methods of determining a relative partition characteristic of a test compound in a target condensate, and methods of determining a condensate preference profile of a test compound are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired relative condensate partition characteristic are provided.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 10, 2020
    Inventors: Bruce Aaron BEUTEL, Peter Jeffrey DANDLIKER, Stephen Paul HALE, Mark Andrew MURCKO, Edgar Erik BOCZEK, Matthäus MITTASCH, Diana Maria MITREA
  • Publication number: 20200253969
    Abstract: Disclosed herein are novel compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the disclosure.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 13, 2020
    Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
  • Publication number: 20200172546
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 4, 2020
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • Publication number: 20200062760
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 27, 2020
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • Publication number: 20030143757
    Abstract: The present invention relates to methods for detecting chemical moieties that may serve as the core or scaffold of a potential drug that is directed to a target. The invention further relates to a chemical library of drug cores and the use of that library to identify useful drug cores for a particular target protein.
    Type: Application
    Filed: October 25, 2002
    Publication date: July 31, 2003
    Inventors: Jonathan Moore, Guy William Bemis, Christopher A. Lepre, Jasna Fejzo, Jeffrey Weilee Peng, Keith Phillip Wilson, Mark Andrew Murcko
  • Patent number: 6127372
    Abstract: This invention provides a novel class of sulfonamide compounds of formula I which are aspartyl protease inhibitors: ##STR1## This invention also provides pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also provides methods for inhibition aspartyl protease activity and methods for treating viral infections using the compounds and compositions of this invention.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: October 3, 2000
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Roger Dennis Tung, Francesco Gerald Salituro, David D. Deininger, Mark Andrew Murcko, Perry Michael Novak, Govinda Rao Bhisetti